1. The antimalarial ferroquine: from bench to clinic
- Author
-
Biot C., Nosten F., Fraisse L., Ter-Minassian D., Khalife J., and Dive D.
- Subjects
malaria ,bioorganometallics ,drug candidate ,ferroquine ,mechanism of action ,resistance ,Infectious and parasitic diseases ,RC109-216 - Abstract
Ferroquine (FQ, SSR97193) is currently the most advanced organometallic drug candidate and about to complete phase II clinical trials as a treatment for uncomplicated malaria. This ferrocenecontaining compound is active against both chloroquine-susceptible and chloroquine-resistant Plasmodium falciparum and P. vivax strains and/or isolates. This article focuses on the discovery of FQ, its antimalarial activity, the hypothesis of its mode of action, the current absence of resistance in vitro and recent clinical trials.
- Published
- 2011
- Full Text
- View/download PDF